Fiche centre
TG Therapeutics Investigational Trial Site
Milwaukee — United States
Essais liés3clinical trials
VilleMilwaukeelocalisation
PaysUnited Stateslocalisation
SourcelocaleCSV/MySQL
Informations
centreSynchronisé depuis ClinicalTrials.gov — NCT05877963
Essais cliniques associés
3| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| ENABLE — A Study Evaluating the Real World Experience of Participants Treated With BRIUMVI® (Ublituximab-xiiy) for Relapsing Multiple Sclerosis (RMS) | SEP | À vérifier | NCT06433752 | ENABLE — A Study Evaluating the Real World Experience of Participants Treated With BRIUMVI® (Ublituximab-xiiy) for Relapsing Multiple Sclerosis (RMS) | RECRUITING |
| Ublituximab | SEP | Phase 3 | NCT05877963 | ENHANCE — Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of Ublituximab | RECRUITING |
| Azercabtagene zapreleucel (azer-cel) | Myasthénie | Phase 1 | NCT06680037 | A Study to Assess the Safety and Clinical Activity of Azer-cel in Participants With B-cell Mediated Autoimmune Disorders | RECRUITING |